Townsend Letter Alternative Medicine Magazine



  FREE e-Edition


 EDTA Chelation Therapy


 E-mail List

From the Townsend Letter
August/September 2015

Inositol Modulation of Essential Metabolic Pathways of Insulin Resistance in Metabolic Syndrome, Polycystic Ovarian Syndrome, and Type 2 Diabetes
by Cristiana Paul, MS, and David M. Brady, ND, DC, CCN, DACBN
Search this site
Page 1, 2, 3

1.      Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012 Jul;28(7):509–515. doi:10.3109/09513590.2011.650660. Epub 2012 Feb 1. Review. PubMed PMID: 22296306.
2.      Fonteles MC, Almeida MQ, Larner J. Antihyperglycemic effects of 3-O-methyl-D-chiro-inositol and D-chiro-inositol associated with manganese in streptozotocin diabetic rats. Horm Metab Res. 2000 Apr;32(4):129–132. PubMed PMID: 10824707.
3.      Kim HJ, Park KS, Lee SK, et al. Effects of pinitol on glycemic control, insulin resistance and adipocytokine levels in patients with type 2 diabetes mellitus. Ann Nutr Metab. 2012;60(1):1–5. doi:10.1159/000334834. Epub 2011 Dec 16. PubMed PMID: 22179130.
4.      Davis A, Christiansen M, Horowitz JF, Klein S, Hellerstein MK, Ostlund RE Jr. Effect of pinitol treatment on insulin action in subjects with insulin resistance. Diabetes Care. 2000 Jul;23(7):1000–1005. PubMed PMID: 10895854.
5.      Kim MJ, Yoo KH, Kim JH, et al. Effect of pinitol on glucose metabolism and adipocytokines in uncontrolled type 2 diabetes. Diabetes Res Clin Pract. 2007 Sep;77 Suppl 1:S247–S251. Epub 2007 Apr 27. PubMed PMID: 17467106.
6.      Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010 Nov–Dec;16(11–12):543–52. doi:10.2119/molmed.2010.00107. Epub 2010 Aug 27. Review. PubMed PMID: 20811656; PubMed Central PMCID: PMC2972396.
7.      Heimark D, McAllister J, Larner J. Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J. 2014;61(2):111–117. Epub 2013 Nov 2. PubMed PMID: 24189751.
8.      Holte J. Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style? J Endocrinol Invest. 1998 Oct;21(9):589–601. Review. PubMed PMID: 9856413.
9.      Franks S, Gharani N, Waterworth D, et al. The genetic basis of polycystic ovary syndrome. Hum Reprod. 1997 Dec;12(12):2641–2648. Review. PubMed PMID: 9455828.
10.    Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005 Apr;26(2):251–282. Epub 2004 Nov 23. Review. PubMed PMID: 15561799.
11.    Strauss JF 3rd, Dunaif A. Molecular mysteries of polycystic ovary syndrome. Mol Endocrinol. 1999 Jun;13(6):800–805. Review. PubMed PMID: 10379878.
12.    1: Carulli L, Rondinella S, Lombardini S, Canedi I, Loria P, Carulli N. Review article: diabetes, genetics and ethnicity. Aliment Pharmacol Ther. 2005 Nov;22 Suppl 2:16–9. Review. PubMed PMID: 16225465.
13.    Ricart W, Fernández-Real JM. Insulin resistance as a mechanism of adaptation during human evolution. [In Spanish.] Endocrinol Nutr. 2010 Oct;57(8):381–390. doi:10.1016/j.endonu.2010.05.003. Epub 2010 Aug 1. Review. Spanish. PubMed PMID:20675202.
14.    Tsatsoulis A, Mantzaris MD, Bellou S, Andrikoula M. Insulin resistance: an adaptive mechanism becomes maladaptive in the current environment – an evolutionary perspective. Metabolism. 2013 May;62(5):622–633. doi:10.1016/j.metabol.2012.11.004. Epub 2012 Dec 20. Review. PubMed PMID: 23260798.
15.    Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013 Oct;95(10):1811–1827. doi:10.1016/j.biochi.2013.05.011. Epub 2013 Jun 10. Review. PubMed PMID: 23764390.
16.    Larner J. D-chiro-inositol – its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002;3(1):47–60. PubMed PMID: 11900279; PubMed Central PMCID: PMC2478565.
17.    Larner J. Inositol, glycogen, insulin, and six nobelists. J Biol Chem. 2013, Apr 26;288(17):12313–12324. doi:10.1074/jbc.X113.471177. Epub 2013 Mar 20. PubMed PMID: 23515311; PubMed Central PMCID: PMC3636915.
18.    Larner J, Allan G, Kessler C, Reamer P, Gunn R, Huang LC. Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy. J Basic Clin Physiol Pharmacol. 1998;9(2–4):127–137. PubMed PMID:10212830.
19.    Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000 Jul;106(2):171–6. Review. PubMed PMID: 10903330
20.    Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol. 2010;2010:476279. doi:10.1155/2010/476279. Epub 2010 Apr 26. Review. PubMed PMID: 20445742; PubMed Central PMCID: PMC2860140.
21.    Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006 Feb;29(2):300–305. PubMed PMID:16443877.
22.    Chang HH, Choong B, Phillips AR, Loomes KM. The diabetic rat kidney mediates inosituria and selective urinary partitioning of D-chiro-inositol. Exp Biol Med (Maywood). Epub 2014 Jul 24. pii:1535370214543064. PubMed PMID:25060739.
23.    Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, Nestler JE. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004 Jan;89(1):242–249. PubMed PMID: 14715857.
24.    Saha L, Kaur S, Saha PK. Pharmacotherapy of polycystic ovary syndrome – an update. Fundam Clin Pharmacol. 2012 Feb;26(1):54–62. doi:10.1111/j.1472-8206.2010.00916.x. Epub 2011 Jan 7. Review. PubMed PMID: 21210850.
25.    Marshall K. Polycystic ovary syndrome: clinical considerations. Altern Med Rev. 2001 Jun;6(3):272–292. Review. PubMed PMID: 11410072.
26.    Murray R. Polycystic ovary syndrome, obesity and insulin resistance: the new female triad. Adv Nurse Pract. August 2004:1–20. Available at
27.    Minozzi M, Nordio M, Pajalich R. The combined therapy myo-inositol plus D-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci. 2013 Feb;17(4):537–540. PubMed PMID: 23467955.
28.    Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997 Dec;18(6):774–800. Review. PubMed PMID: 9408743.
29.    Galazis N, Galazi M, Atiomo W. D-chiro-inositol and its significance in polycystic ovary syndrome: a systematic review. Gynecol Endocrinol. 2011 Apr;27(4):256–262. doi:10.3109/09513590.2010.538099. Epub 2010 Dec 10. Review. PubMed PMID: 21142777.
30.    Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord. 2010 Apr;8(2):127–36. doi:10.1089/met.2009.0052. PubMed PMID: 20156067; PubMed Central PMCID: PMC3140116.
31.    Nestler JE, Jakubowicz DJ, Iuorno MJ. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2000;13 Suppl 5:1295–1298. Review. PubMed PMID: 11117673.
32.    Cheang KI, Baillargeon JP, Essah PA, et al. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism. 2008 Oct;57(10):1390–1397. doi:10.1016/j.metabol.2008.05.008. PubMed PMID: 18803944; PubMed Central PMCID: PMC2574418.
33.    Ireland K, Child T. Polycystic ovary syndrome and the postmenopausal woman. J Br Menopause Soc. 2006 Dec;12(4):143–148. Review. PubMed PMID: 17178014.
34.    Starka L, Duskova M, Cermakova I, Vrbiková J, Hill M. Premature androgenic alopecia and insulin resistance. Male equivalent of polycystic ovary syndrome? Endocr Regul. 2005 Dec;39(4):127–131.PMID:16552990
35.    Stárka L, Cermáková I, Dusková M, Hill M, Dolezal M, Polácek V. Hormonal profile of men with premature balding. Exp Clin Endocrinol Diabetes. 2004 Jan;112(1):24–28.PMID:14758568
36.    Genazzani AD, Santagni S, Rattighieri E, et al. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol. 2014 Jun;30(6):438–443. doi:10.3109/09513590.2014.897321. Epub 2014 Mar 7. PubMed PMID: 24601829.
37.    Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012 May;16(5):575–581. PubMed PMID: 22774396.
38.    Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol. 2014 Mar;30(3):205–208. doi:10.3109/09513590.2013.860120. Epub 2013 Dec 19. PubMed PMID: 24351072.
39.    Reaven GM. Syndrome X: 6 years later. J Intern Med Suppl. 1994;736:13–22.
40.    Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem. 2005 Jun;51(6):931–938. Epub 2005 Mar 3. Review. PubMed PMID: 15746300.
41.    Reaven GM. The metabolic syndrome: is this diagnosis necessary? Am J Clin Nutr. 2006 Jun;83(6):1237–1247. Review. Erratum in: Am J Clin Nutr. 2006 Nov;84(5):1253. PubMed PMID: 16762930.
42.    Giordano D, Corrado F, Santamaria A, Quattrone S, Pintaudi B, Di Benedetto A. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause. 2011 Jan;18(1):102–104. doi:10.1097/gme.0b013e3181e8e1b1. PubMed PMID: 20811299.
43.    Santamaria A, Giordano D, Corrado F, Pintaudi B, Interdonato ML, Vieste GD. One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric. 2012 Oct;15(5):490–495. doi:10.3109/13697137.2011.631063. Epub 2011 Dec 23. PubMed PMID: 22192068.
44.    Capasso I, Esposito E, Maurea N, Montella M, Crispo A, De Laurentiis M. Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial. Trials. 2013 Aug 28;14:273. doi:10.1186/1745-6215-14-273. PubMed PMID: 23981814; PubMed Central PMCID: PMC3765513.
45.    Malvasi A, Casciaro F, Minervini MM, et al. Myo-inositol, D-chiro-inositol, folic acid and manganese in second trimester of pregnancy: a preliminary investigation. Eur Rev Med Pharmacol Sci. 2014;18(2):270–274. PubMed PMID: 24488919.
46.    Evans JL, Goldfine ID. Alpha-lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther. 2000 Autumn;2(3):401–413. Review. PubMed PMID: 11467343.
47.    Ansar H, Mazloom Z, Kazemi F, Hejazi N. Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. Saudi Med J. 2011 Jun;32(6):584–588. PubMed PMID: 21666939.
48.    D'Anna R, Di Benedetto V, Rizzo P, et al. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol. 2012 Jun;28(6):440–442. doi:10.3109/09513590.2011.633665. Epub 2011 Nov 28.
49.    D'Anna R, Scilipoti A, Giordano D, Caruso C, Cannata ML, Interdonato ML. Myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care. 2013 Apr;36(4):854–857. doi:10.2337/dc12-1371. Epub 2013 Jan 22. PubMed PMID: 23340885;PubMed Central PMCID: PMC3609506.
50.    Corrado F, D'Anna R, Di Vieste G, et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. 2011 Aug;28(8):972–975. doi:10.1111/j.1464-5491.2011.03284.x. PubMed PMID: 21414183.
51.    Fulghesu AM, Ciampelli M, Muzj G, et al. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril. 2002 Jun;77(6):1128–1135. PubMed PMID: 12057717.
52.    Pereira S, Shah A, Fantus IG, Joseph JW, Giacca A. Effect of N-acetyl-L-cysteine on insulin resistance caused by prolonged FFA elevation. J Endocrinol. Epub 2015 Jan 21. pii:JOE-14-0676. PubMed PMID:25609734.
53.    Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999;340: 1314–1320.
54.    Iuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002;8:417–423.
55.    Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci. 2007 Sep–Oct;11(5):347–354. PubMed PMID: 18074942
56.    Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci. 2009;13(2):105–110.
57.    Laganà AS, Barbaro L, Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D Chiro-Inositol. Arch Gynecol Obstet. Epub 2014 Nov 22. PubMed PMID: 25416201.
58.    Sacchinelli A, Venturella R, Lico D, et al. The efficacy of inositol and N-acetyl cysteine administration (ovaric HP) in improving the ovarian function in infertile women with PCOS with or without insulin resistance. Obstet Gynecol Int. 2014;2014:141020. doi:10.1155/2014/141020. Epub 2014 Apr 30. PubMed PMID: 24876842; PubMed Central PMCID: PMC4021745.
59.    Hong JH, Jang HW, Kang YE, et al. Urinary chiro- and myo-inositol levels as a biological marker for type 2 diabetes mellitus. Dis Markers. 2012;33(4):193–199. doi:10.3233/DMA-2012-0925. PubMed PMID: 22960342; PubMed Central PMCID: PMC3810682.
60.    Kim BH, Park JY, Jang JB, Moon DC. LC-MS/MS method for the quantification of myo- and chiro-inositol as the urinary biomarkers of insulin resistance in human urine. Biomed Chromatogr. 2012 Apr;26(4):429–433. doi:10.1002/bmc.1682. Epub 2011 Aug 9. PubMed PMID: 21830227.
61.    Villeneuve MC, Ostlund RE Jr, Baillargeon JP. Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity. Metabolism. 2009 Jan;58(1):62–68. doi:10.1016/j.metabol.2008.08.007. PubMed PMID: 19059532.
62.    Stull AJ, Thyfault JP, Haub MD, Ostlund RE Jr, Campbell WW. Relationships between urinary inositol excretions and whole-body glucose tolerance and skeletal muscle insulin receptor phosphorylation. Metabolism. 2008 Nov;57(11):1545–51.doi:10.1016/j.metabol.2008.06.009. PubMed PMID: 18940392; PubMed Central PMCID: PMC3469253.
63.    Larner J, Craig JW. Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance. Diabetes Care. 1996 Jan;19(1):76–8. PubMed PMID: 8720541.
64.    Isabella R, Raffone E. Does ovary need D-chiro-inositol? J Ovarian Res. 2012 May 15;5(1):14. PubMed PMID: 22587479; PubMed Central PMCID: PMC3447676.

Page 1, 2, 3

Cristiana Paul, MS
Independent Nutrition Research Consultant, Product Development Consultant for Designs for Health Inc., Suffield, Connecticut (US)

David M. Brady, ND, DC, CCN, DACBN
Vice Provost, Division of Health Sciences; Director, Human Nutrition Institute; Associate Professor, University of Bridgeport, Bridgeport, Connecticut (US); Chief Medical Officer, Designs for Health Inc., Suffield, Connecticut (US), and Diagnostic Solutions Laboratory LLC, Alpharetta, Georgia (US)

Christiana PaulCristiana Paul holds a Masters in Nutrition Science from Cal Poly Pomona, California, and has extensive experience in clinical practice and reviewing nutrition research. She has been formulating nutritional supplements and integrative medicine protocols for 15 years, always with a vision ahead of the curve.

She is a contributor to the 2012 edition of Textbook of Natural Medicine (edited by Joseph Pizzorno & Michael Murray) with a chapter review on vitamin K1/K2/K3 and one on long chain omega-3 fatty acids. She was on the editorial board of Journal of American Nutraceutical Association, a peer-reviewed journal on nutraceutical interventions and is a contributor to the think tank Gerontological Research Group.

She has lectured for healthcare practitioner seminars in US and internationally on various topics such as: metabolic determinants of body composition, immune function, age management and new concepts in dietary proteins. In her published medical/nutritional journal articles and interviews, she addressed topics for which she is considered an expert: paradigm shift in vitamin K applications, mechanisms of actions for natural anti-inflammatories versus pharmaceutical drugs, nutraceutical interventions for managing hypertension, diabetes, insulin resistance, healthy aging, fat loss, and objective testing for nutritional status.
She is currently a product/protocol development consultant for Designs for Health, a professional line of supplements. Learn more at

Dr. David M. Brady has over 23 years of experience as an integrative physician and over 19 years in health sciences academia. He is a licensed naturopathic medical physician in Connectucut and Vermont, and a dual-board-certified clinical nutritionist and received his original clinical training as a chiropractic physician. He currently serves as the vice provost for the Division of Health Sciences, director of the Human Nutrition Institute, and an associate professor of Clinical Sciences at the University of Bridgeport in Connecticut. He maintains a private practice, Whole Body Medicine, in Fairfield, Connecticut. Dr. Brady is also the chief medical officer for Designs for Health Inc. and Diagnostic Solutions Laboratory LLC. He is an internationally sought-after presenter and has appeared on the plenary speaking panel of some of the largest and most prestigious conferences in the field. Dr. Brady has published a multitude of peer-reviewed scientific papers and textbooks related to chronic pain, autoimmunity, and functional gastroenterology and is a featured contributing author in the medical textbooks Advancing Medicine with Food and Nutrients 2nd ed. (Kohlstadt I, CRC Press, Boca Raton, Florida; 2012), Integrative Gastroenterology (Mullin G, Oxford Press, Weil Integrative Medicine Library, New York, New York; 2011), and Laboratory Evaluations for Integrative and Functional Medicine 2nd ed. (Bralley JA, Lord RS, Metametrix Institute. Duluth, GA. 2008). His latest popular book is titled Dr. Brady's Healthy Revolution: What You Need to Know to be Healthy in a Sick World. You can learn more at

Consult your doctor before using any of the treatments found within this site.

Subscriptions are available for Townsend Letter, the Examiner of Alternative Medicine
magazine, which is published 10 times each year. Search our pre-2001 archives for further information. Older issues of the printed magazine are also indexed for your convenience.
1983-2001 indices ; recent indices. Once you find the magazines you'd like to order, please
use our convenient form, e-mail, or call 360.385.6021.


Fax: 360.385.0699

Who are we? | New articles | Featured topics | e-Edition |
Tables of contents
| Subscriptions | Contact us | Links | Classifieds | Advertise |
Alternative Medicine Conference Calendar | Search site | Archives |
EDTA Chelation Therapy | Home

© 1983-2015 Townsend Letter
All rights reserved.
Website by Sandy Hershelman Designs